Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$EDXC - EndexxCorp has been working on:
1. Herb House in Ocho Rios is ready for Jamaican Cruise traffic
2. BlessWell Chicago Pop-up re-started
3. Major FMD retailer orders started
I'm thinking the company will hit another spike.
CBD industry is blowing up! $EDXC - @EndexxCorp's flagship product, CBD Unlimited, is taking the industry by storm with measured, predictable doses and the highest quality. It may spike stock in the near future!
Stocks are generally falling now, excellent opportunity to get in to a serious play.Yesterday I have added more QBL to my investments.
Indicators show highly oversold market and trend reversal will likely come any day now.
That said, it might not be a skyrocket change - though it will go up. If you are considering this stock, I would suggest the Half-Year report as a valuable startingpoint to get the overall picture. It came out 2 days ago and is a good sum up to all of QBL-story until 31 december 2017.
Thinking "outside the box", is difficult sometimes, the QBL story is not a typical pennystock. When you evaluate the facts doing due dilligence, I like the various sources to get Revenue AND the millions of cash in the bank.
Experience is worth a lot when evaluate management and "Diamond Rose" got plenty. The team and different collaborations/JV/partners she has setup is the best I`ve seen in a pennystock ! I am confident this is and will continue to be a big winner in the long run.
MMJ cannatab delivery from Canada, approval process on the go. Some day in this month QBL will get good news; GMP- certified plant sends the first products ready for the very lucrative PHARMA market.
With approval done we will see a big jump - to be able to deliver a set of various MMJ formulations (GMP/Pharmagrade approved) is BIG. How big is hard to say - revenue will be a way to measure it.
With Commonwealth countries, these products will be available to a big market. Australia, Canada and UK is main markets with a demand and equal laws regarding MMJ goverment regulations.
There targeting of neighbour Asia next door will be a gamechanger - key (if plans workout); the MMJ producer who gets the lionpart there... since Australia already export to Asia with a long established tradition, it can be a advantage to the North-american competion.
Politically US has lost some good-will since Mr Trump has said some hard words towards some of the Asian countries - he accuse some of them why US has a tough time within the trading area etc.
https://docs.wixstatic.com/ugd/1943b6_9a2f1ccc39554b11917750e578545fad.pdf
More importantly; QBL will be first out with this new pharma option.
QBL.AX is the ticker. (see board further info)
World First for MCL in Autoimmune Disease Research.Feb 26, 2018 - (ABN Newswire) MCL subsidiary of QBL.
Another dot connecting... all the parts getting togheter in success.
SUMMARY at the bottom part of the news. Important; The "BIG LETTER" part, "Highlights" and "WORTH SEE"
http://www.4-traders.com/QUEENSLAND-BAUXITE-LTD-11939085/news/Queensland-Bauxite-Ltd-ASX-QBL-A-World-First-for-MCL-in-Autoimmune-Disease-Research-26053610/
The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its subsidiary company Medical Cannabis Limited (MCL) through its wholly owned subsidiary Medical Cannabis Research Group Pty Ltd (MCRG), has signed a Research Funding Agreement with the Research & Development Foundation at the Technion Institute, Haifa, Israel. The agreement revolves around the research of Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion Institute.
Cannabis as a Potential Therapy for Multiple Sclerosis
According to the agreement MCRG will sponsor the continued Research of how the cannabis plant can be used for the treatment of Multiple Sclerosis (MS). Prof. Meiri has identified the synergistic relationship between the Cannabis plant and the human genome that will form the basis for this research.
Highlights
- Medical Cannabis Ltd (MCL) a subsidiary of Queensland Bauxite Limited (ASX:QBL), completes an arrangement to sponsor research into medical cannabis treatments for Multiple Sclerosis (MS).
- MCL through its Medical Cannabis Research Group Pty Ltd (MCRG) has signed an agreement with the Technion Research & Development Foundation for the performance of research by Prof. David (Dedi) Meiri, from the Faculty of Biology at the Technion - Israel Institute of Technology in Haifa, Israel. Prof. Meiri is Head of the Technion's Cannabis research team. According to the agreement, MCRG will sponsor research into how the cannabis plant can be used in the treatment of symptoms and halting the progression of autoimmune diseases with special emphasis on Multiple Sclerosis (MS).
- Long-standing and approved MS treatments can reduce relapses, but current solutions may slow down, but ultimately do not arrest the progression of the disease.
- The overall objective of Prof. Meiri's study is to identify specific cannabis compounds that can be used in clinical trials as a potential treatment for Multiple Sclerosis (MS).
- MCL through its Medical Cannabis Research Group (MCRG) will agree to fund Research into Prof. Meiri's study in return for an exclusive license for any product derived from the Research.
- Should a successful product eventuate, the Board believes, in time, this Research has the potential to be a global medical 'game changer' for MS sufferers, and a material revenue stream for MCL.
- MCRG has committed to fund USD$3M over a 3-year period, towards the research budget, in return for an exclusive license of any product to be developed from this research for MS, or potentially for any product that could alleviate or treat any other auto immune disease that could be developed from this research.
Pnina Feldman, Executive Chairperson of QBL says: "The Boards of QBL and MCL feel privileged to be working with Prof. Meiri and his team of medical cannabis researchers at the Technion-Israel Institute of Technology, not only for the opportunity to be in with top researchers who are one of the leaders in the world with this research, and not only to commercialise the products that may result from this research, but for this unique and ground-breaking opportunity to work diligently towards the betterment of health worldwide.
Everyone knows someone with an- autoimmune disease in one form or another, and there could be no more satisfying outcome, or more important work, than making the lives of these people not only easier, but hopefully enabling respite from symptoms and cures for disease. The benefits of the age-old cannabis plant, combined with state of the art medical technology, is opening new horizons, and we are both proud and humbled to be amongst the pioneers supporting and being a part of this amazing research."
Assistant Professor, Heads the "Laboratory of Cancer Biology and Cannabinoid Research", Technion, Israel Institute of Technology, Israel.
David (Dedi) Meiri, PhD, is an Assistant Professor at the Faculty of Biology at the Technion Israel Institute of Technology and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri's scientific background is highly diverse. He holds a M.Sc. in biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. Dr. Meiri conducted his post-doctoral fellowship at the Ontario Cancer Institute where he expanded his knowledge in human biology and cancer pathogenesis and focused on the role of the GEF-H1 protein in tumor invasion and metastasis. Upon completion of his post-doctoral fellowship, Dr. Meiri took a position at the Technion Israel Institute of Technology, where he heads the "Laboratory of Cancer Biology and Cannabinoid Research".
Presently, his lab investigates the therapeutic potential of phytocannabinoids, the unique active compounds of the Cannabis sativa plant. On top of other research being conducted in the lab, the main focus of his research is to determine the antitumor effects of cannabinoids, including the anti-metastatic and pro-apoptotic effects of phytocannabinoids.
From the establishment of his lab it has grown significantly and it is now comprised of 38 scientists; a highly trained team of skilled plant biologists, chemists, cancer experts and neuroscientists who work together in synergy to complement one another in order to achieve the highest level of results.
Dr. Meiri's lab, is one of the leading laboratories in the world that is exceptionally equipped with the capabilities and resources to ask and answer almost any question in the field of medical cannabis.
Dr. Meiri operates the "Cannabis Database Project" and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment, such as: colon disease, pain prevention, cancer treatment and epilepsy. He collaborates with cannabis growers, clinicians and major manufacturers and distributors of medical cannabis, including Andrew Kavasilas from QBL: MCL in the purpose of revolutionizing cannabis treatment.
Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees which seek to advance the fundamental understanding of optimal cannabis usage and minimization of adverse side effects.
Background - Technion Israel Institute of Technology
Technion - Israel Institute of Technology was founded in 1912 in Haifa and is the oldest university in IsraelThe Institute is currently rated #93 in the World's Top 500 Universities and is the only Israeli university in the top 100 of the list. (2017 - Shanghai Ranking World Leading Universities)
Technion researchers, including three Nobel laureates in chemistry, have won many International awards for their research in the fields of Microbiology, Microbial Diagnostics, Genomics, Antibiotics to name just a few. Technion people, ideas and inventions make immeasurable contributions to the world including life-saving medicine, sustainable energy, computer science, water conservation and nanotechnology.
Technion is widely recognized as a global leader in Medical Cannabis Research. Israel has been leading the world since the early 1960's in Medical Cannabis research.
In November 2017, Times Higher Education ranked Technion as the world's leading academic institution in teaching digital skills to students, ahead of the prestigious American M.I.T. University.
(WORTH TO SEE !)
Background - Autoimmune disease
The Australian Society of Clinical Immunology and Allergy (ASCIA) states that autoimmune diseases affect around 5% of people and are one of the most important health issues in Australia and New Zealand.
An autoimmune disease is a disease in which the body's immune system attacks healthy cells. The most common types of autoimmune diseases include:
- Rheumatoid Arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Lupus: An inflammatory disease caused when the immune system attacks its own tissues.
- Celiac Disease: An immune reaction to eating gluten, a protein found in wheat, barley and rye.
- Multiple Sclerosis: A disease in which the immune system eats away at the protective covering of nerves. This condition can last for years or be lifelong. In MS resulting nerve damage disrupts communication between the brain and the body.
- Type 1 Diabetes: A chronic condition in which the pancreas produces little or no insulin.
- Other diseases include: Sjogren's syndrome, Polymyalgia rheumatica, Ankylosing spondylitis, Alopecia areata, Vasculitis, Temporal arteritis, Crohn's disease, Graves disease (thyroid) etc. In all, there are 80 known autoimmune diseases, with an estimated 50 million Americans suffering these diseases in increasing numbers.
The disorders range in severity from mild to disabling, depending on which system of the body is under attack and to what degree.
The causes of autoimmune diseases are unknown. In many cases it appears that there is some hereditary tendency. However, other factors such as injections and some drugs may play a role in triggering autoimmune diseases.
No Known Cure
Autoimmune disorders in general have no known cure, but the conditions can be somewhat controlled and managed in many cases.
Treatments
Historically, treatments include:
- Anti-inflammatory drugs - to reduce inflammation and pain.
- Corticosteroids - to reduce inflammation. They are sometimes used to treat an acute flare of symptoms.
- Pain-killing medication - such as paracetamol and codeine.
- Immunosuppressant drugs - to inhibit the activity of the immune system.
- Physical therapy - to encourage mobility.
- Treatment for deficiency - for example insulin injections in the case of diabetes.
- Surgery - for example to treat bowel blockage in the case of crohn's disease.
- High dose immunosuppressants - the use of immune system suppressing drugs (in the doses needed to treat cancer or to prevent the rejection of transplanted organs), have been tried recently, with promising results. Particularly when intervention is early, the chance of a cure with some of these conditions seems possible.
- Stem cell Research - Recent experimentation in Israel with stem cell implanting to treat impaired bodily functions is being trialled and although very invasive is showing some progress.
The goal of the cannabis research in the field of auto immune disease is to find a treatment and possible cure that does not have the serious side effects of other treatments being researched or used to date.
The Role of Cannabis in Autoimmune Diseases
So far, the approved and available treatment for autoimmune diseases with medicinal cannabis, has been in the area of pain relief, the cannabis formula replacing morphine and its derivatives, with morphine in high and frequent doses being serviceable mainly in palliative care. The medicinal cannabis pain relief available for (MS) for example, is most effective in relieving pain, enabling sufferers to function better without the side effects of pain relieving drugs such as morphine. The danger of morphine has been recognized by the Australian authorities, who as of February 1, 2018 requires codeine to be a prescription only drug.
Andrew Kavasilas, Technical Director of MCL, said: "This is a very logical avenue of research, especially when the only semi-legal Cannabis medicine in the world was developed for the treatment of MS. That was a first wave cannabinoid medicine and a vast amount of knowledge has been gained since then. There's an incredible amount of work being done in Israel which has capitalised on many opportunities due to their government's willingness to allow medical Cannabis use by well over 100 000 people, while the profession scientific research catches up to break down all this valuable evidence".
Dr David (Dedi) Meiri - Cannabis as a Potential Therapy for Multiple Sclerosis
Due to the legal access to medical researchers and doctors of high and low THC Cannabis plants under the auspices of the Israeli Health Department, Israel is currently at the forefront of medicinal cannabis research, and the world-renowned Dr Meiri is arguably today's leading medicinal cannabis researcher in Israel, if not in the world.
Dr Meiri is head of the Technion's Cannabis Research team and will be the principal investigator in research to be funded by MCRG (the research and wholly owned subsidiary company of MCL). Dr Meiri lectures and teaches about the latest developments in cannabis research throughout the world, and has recently been on a lecture tour to Australia, speaking in Sydney at a function organized at Wolper hospital for doctors interested in Dr Meiri's new and exciting research insights.
Assisting Dr Meiri's team of close to 30 researchers, will be supporting investigators Dr Igal Louria-Hayon PhD and Dr Gil Lewitus PhD.
Overall Objective
The overall objective of Dr Meiri's study is to match effective cannabis extracts and specific cannabinoids composition that regulate/modulate immune function, specifically, autoimmunity in MS in order to optimize treatment for MS patients.
It is hoped that achieving a successful outcome of the overall objective could lead to a possible cure for MS through the strengthening of the immune system, which in turn will assist the research into other auto immune diseases and diseases in general.
Dr Meiri Comments:
"Although current treatment of MS with broad-spectrum immunomodulatory drugs reduces immune cell activity and entry into the central nervous system (CNS) and decreases relapse frequency, they are often associated with side effects, ranging from flu-like symptoms to the development of other auto-immune disorders; fatal opportunistic infections such as progressive multifocal leukoencephalopathy; and other malignancies.
"These side effects highlight the need to identify more specific therapeutic targets that can be effectively modulated without inducing such adverse reactions. In addition, it is increasingly acknowledged that although the long-standing and approved MS treatments can reduce relapses, they do not ultimately halt the disease. Therefore, neuroaxonal damage, which results in progressive physical disability, continues to accumulate and becomes permanent throughout the disease progression.
"Recently, the therapeutic potential of phytocannabinoids, the unique active compounds of the cannabis plant, has been discovered in the area of immunology; More than 140 phytocannabinoids have been identified within the cannabis plant. A few specific natural and synthetic cannabinoids have been proposed to have therapeutic potential for various diseases. The U.S. Food and Drug Administration (FDA) recently approved the use of several synthetic cannabinoids to be available by prescription for pain relief treatment.
"Cannabinoids have been largely characterized for their action in the immune system and were tested in several in vitro and in vivo disease models for inflammation (a common symptom of numerous autoimmune diseases).
Recent research showed that administration of tetrahydrocannabinol (THC) with mice triggered significant caspase medicated cell death in T cells and dendritic cells, resulting in immunosuppression. In addition, other research demonstrated that cannabinoids downregulate cytokine and chemokine production and at times upregulate T regulatory cells as a mechanism to suppress inflammatory responses. The targeted actions of cannabinoids in the endocannabinoid system is also involved in immunoregulation.
"CDB another abundant cannabinoid was found to exhibit a suppressive effect on T cell functional activities via reducing IL-17 cytokine secretion, a key autoimmune factor which was also shown to be involved in multiple sclerosis (MS). In this context, its additional neuroprotective effects, which included the upregulated of a number of anti-oxidative genes (e.g. those of glutathione synthesis) in CBD exposed microglial cells from inflammation-induced apoptosis may significantly enhance its anti-inflammatory beneficial properties and account for alleviation of MS pathology.
"As of now, there are several different cannabinoid medications approved for patients with MS, inducing cannabis in its natural form. Cannabis is primarily used to reduce muscle stiffness and pain. However chemical trials to date done with specific cannabinoids showed small or no effect on disease progression from the above current cannabinoid medications.
"Other compounds in Cannabis have been poorly studied regarding their potential immunosuppressive effects. For example, it has been shown that terpenoids are key components of cannabis activity as they are known to participate in making the plant extract more potent than synthetic cannabinoids. Overall, Cannabis's multiple inflammatory effects on various immune cell types, together with the vast number of phytocannabinoids and different ratios of cannabinoids in different strains makes the Cannabis plant a complex matrix with great therapeutic potential.
"Cannabis chemical composition analyses currently focus on identifying and qualifying and quantifying several major Cannabinoid types including THC, CBD, and in some recent studies also cannabichromene (CBC), cannabinol (CBN), and cannaligerol (CBG). Other Cannabis compounds which may be important for their therapeutic effects, have predominantly been neglected.
"In order to identify more cannabinoid types, we developed, in our lab, a novel ability to analyze the metabolomics and the specific chemical composition of cannabis plants.
"As far as we know, 'WE ARE THE ONLY LAB IN THE WORLD TODAY THAT HAVE THESE ABILITIES OF COMPREHESIVELY PROFILING THE CANNABINOID COMPOSITION FOR A VARIETY OF CANNABIS STRAINS AND ALSO TO BE ABLE TO PURIFY SINGLE PHYTO-CANNABINOIDS AND CREATE "SUSPECT PROFILES" FOR EXAMINATION IN DIFFERENT TYPES OF STUDIES.'
Research Plan
"In the last year, we established the novel ability to analyze the metabolomics and the specific chemical composition of Cannabis plants (principally of phytocannabinoids and terpenes). We intend to identify the effects of different cannabinoids and terpenes both individually and in combination on the function of immune cells, specifically on MS-derived autoimmune and regulatory cells in vitro. We intend to evaluate the immunomodulatory properties of specific cannabinoid extracts in in vivo rodent models of MS. This will enable us to detect the most effective extracts in in vivo rodent models of MS. This will enable us to detect the most effective Cannabis extract and cannabinoid profiles for regulating immunopathology in MS.
Specific Aims
- Characterize clinically-used Cannabis strains using comprehensive mass-spectrometry based metabolomics.
- Screen for the immunoregulatory properties of different Cannabis extracts on immune cell function and MS immunopathology.
- Demonstrate the immunomodulatory properties of specific Cannabis extracts on various MS rodent models and identify specific compounds that can then be used in clinical trials as potential treatment for MS.
Significance
"Affecting millions of people worldwide, Multiple Sclerosis (MS) is the most common autoimmune disorder affecting the central nervous system. Therapies for MS are only partially effective and there is no known cure. Therefore, there exists a great and unmet clinical need for the development of neuroprotective treatments. Today, MS patients are treated with medical Cannabis primarily for the palliative purposes. Furthermore, the specific Cannabis strain for palliative treatment is chosen arbitrarily. Consequently, evaluating the immunomodulatory properties of Cannabis in MS and tailoring the best combination of phytocannabinoids may open new treatment possibilities for MS patients with the intention of finding a cure."
Summary
"In this work we aim to elucidate the immunoregulatory properties of phytocannabinoids and terpines in MS, as well as further investigate Cannabis's mechanisms of action in these areas. This research not only has the ability to advance the identification of new drug candidates, but also advance our abilities to optimize Cannabis treatment options and efforts towards the creation of personalized medicine for MS patients."
Pnina Feldman, Executive Chairperson and Director of Business Development of QBL stated: "Having had the pleasure of meeting Dr David Meiri at the Wolper Doctors Conference, in Australia, in June 2017, I was very happy for the opportunity to open a dialogue with Dr Meiri, which was the beginning of this current deal. We are very excited about the work being carried out by Dr Meiri, and his team at Technion, and we believe that this research will hopefully be of major benefit worldwide, and in particular to QBL shareholders who support our ground-breaking work."
To view figures, please visit:
http://abnnewswire.net/lnk/4V8V11WC
About Queensland Bauxite Ltd:
Queensland Bauxite Limited (ASX:QBL) is an Australian listed company focused on the exploration and development of its bauxite tenements in Queensland and New South Wales. The Company's lead project is the South Johnstone Bauxite Deposit in northern Queensland which has rail running through the project area and is approximately 15-24 kilometres from the nearest deep water port. The Company intends to become a bauxite producer with a focus on commencing production at South Johnstone as early as possible. The Company also pursues additional investment opportunities, and has acquired a 55% shareholding in Medical Cannabis Limited, an Australian leader in the hemp and Cannabis industries.
Contact:
Queensland Bauxite Ltd
Tel: +61-2-9291-9000
For further information or any queries please email the Company at:
sfeldman@queenslandbauxite.com.au
Copyright (C) 2018 ABN Newswire. All rights reserved., source Press Releases English
Here is another!!
Charts
PAOG
PAOG Heikin Ashi Chart
RSII
RSII Heikin Ashi Chart
SIGO
SIGO Heikin Ashi Chart
POTN
POTN Heikin Ashi Chart
RSHN
RSHN Heikin Ashi Chart
LVVV
LVVV Heikin Ashi Chart
AMFE
AMFE Heikin Ashi Chart
MRMD
MRMD Heikin Ashi Chart
INMG
INMG Heikin Ashi Chart
SIPC
SIPC Heikin Ashi Chart
VATE
VATE Heikin Ashi Chart
MJX
MJX Heikin Ashi Chart
Thank you for the update.
Another reason to visit Sandusky County besides going to Cedar Point.
$SIGO - back in play! Accumulation phase initiated!
$$Join the ABVG facebook group$$
https://www.facebook.com/groups/134292233858820/
$SIGO just put out an 8K. they are reducing the O/S to 4M.
SIGO 8K: http://ih.advfn.com/p.php?pid=nmona&article=75480069&symbol=SIGO
Good luck!
VAPI Float 10 million
Take a look at VAPI Vapir.com. Awesome vaporizers. Super high quality product. High quality company, current on all their filings. Low float (Insider holds approx. 80%), low o/s, only down here due to CDEL shorting it because no eyes on the stock. This will skyrocket if any volume comes in it. See company website, really nice quality site. Nice MJ play with room to run.
All my opinion, please do your own DD.
Grand Opening today at Sandusky, Ohio Marijuana Medical Clinic NWAV
Advertisement
Full Page Ad 5-24-17 Sandusky Register
Marijuana Medical Card
http://www.altmedcenters.com/
http://pao.group/
PAO Group, Inc. Releases Q1 Financials Demonstrating Revenues; Details Shareholder Conference Call with Anticipated Near-Term Growth
https://finance.yahoo.com/news/pao-group-inc-releases-q1-134439086.html
PAO Group, Inc. Anti-Opiate Crusade Charges on with Opening of Flagship Location in State of Ohio
http://ih.advfn.com/p.php?pid=nmona&article=74318199
PAO Group, Inc. Focusing on 2017 Growth Expansion Initiatives
http://ih.advfn.com/p.php?pid=nmona&article=72741925
NWAV ROADTRIP SUMMARY & REPORT
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130328503
St Augustine, Florida Medical Clinic
Rec my man thanks for your reply....I am just updating the board about some NWAV updates....To your success REC!!!
NWAV Conference Call Scheduled....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131183284
NWAV Tier Change....
http://www.otcmarkets.com/market-activity/otc-tier-changes?search=nwav&searchType=symbol
Thanks for the update GrooveMaster and continued successful trading/investing to you with your positions.
As I mentioned, NWAV appears to have a nice thing going, but I haven't followed intimately and I can't be in everything.
My focus remains on a few other positions right now.
Respectfully,
Rec
Updated DD Rec...NWAV just went current on OTC filings!!!
http://www.altmedcenters.com/
http://pao.group/
This link shows a dispensary. NWAV
http://pao.group/store/
PAO Group, Inc. Anti-Opiate Crusade Charges on with Opening of Flagship Location in State of Ohio
http://ih.advfn.com/p.php?pid=nmona&article=74318199
PAO Group, Inc. Focusing on 2017 Growth Expansion Initiatives
http://ih.advfn.com/p.php?pid=nmona&article=72741925
NWAV ROADTRIP SUMMARY & REPORT
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130328503
St Augustine, Florida Medical Clinic
I marked the Board with a follow.
Thank You very much!!
Sign up for email alerts if you want his weekly "money mail"
https://investorshub.advfn.com/FLEX-NATION-25117/
Kool./
I am not familiar with Flex at all.
We do have some good stocks
I just got Flex's money mail and he says we are "gambling" by golly!!! If you do not know what I am talking about....the Flex Nation board has a Sunday email blast called the "money mail".....Flex has a lot of experience and he always stresses exercising caution....LOL
Anyway I think we are in some good stocks which is not to common down here...
Yes, I see what You are talking about.
I only became premium 3 Years ago.
Make more Friends that way.
And learn from other Good Investors like You.
I got You followed too.
I was going to Member Mark you but I already have. I forgot....LOL
GLTY
GoodBuddy!!! I got you beat by 4 days.....I have been on Ihub 4 days longer than you....LOL I joined 3-25-2003 and you joined 3-29-2003...LOL I sure wish I would have joined and got Grandfathered......I have wished that more than once. I think I was reading then ...just had not joined. I am user 20237 and you are user 20310....so 73 people joined in that short time. I believe they cut the Grand Father off at the first 8000 users....
Yes, I agree, NWAV is a great stocks.
Yes, the next Two Years will make more and more baby boomers Millionaires.
Or any investor who has faith in Marijuana prohibition ending.
Yes, I am in RSII...but not NWAV.
______________________________________________________
Got My boat floating on AMFE.
That company is much more than a Marijuana Play!!
Safest "PINK" Penny Stock that I have ever owned.
Last Two Quarters profitable and they haven't even announced what Marijuana Grower that the GroZone system will be installed with.
Yes I did!!! Exciting times GoodBuddy!!! LOL Are you in RSII? I do not read that board and I do not recall seeing you on the NWAV board? I traded RSII in the beginning.....I am all in on NWAV now!!! Turned into a long investor....LOL I missed GIGL last 1000% run to go all in on NWAV....I would have another 4 million shares at least had I been a little more patient. Have a good weekend!!
Did You notice New Wave and RSII have the same CEO?
I can only manage a few positions myself. However I have been watching Pistol Pete and I have not asked him but it seems to me he holds over 20 positions and maybe quite a bit more than that. Meanwhile he posts over 200 messages a day and somehow he is making trades....I saw him mention I believe in January where he was up $50,000. At least I believe that was what he said and it sounded like for the month....LOL He amazes me with all his activity and success if that is the case...LOL Anyway if you end up lightening your load come join us over at NWAV..you would be much welcomed!!
The best to you!!
Yes I have GrooveMaster and I like NWAV. However, I can't be in them all.
When it comes to the OTC, generally speaking I try not to be in more than 5 positions due to the erratic volatile behavior of most, with the exception of free share positions.
Generally speaking, when I'm an active holder of any OTC stock, I try to familiarize myself intimately with the trading behavior so as to beneficially trade into a free position. That's why I try to limit my active OTC positions.
Currently, I'm not looking to add another position. There will always be opportunities, so I stay disciplined with my normal approach.
Thank you though!
Respectfully,
Rec
Here are the NWAV websites!!!
http://www.altmedcenters.com/
http://pao.group/
This link shows a dispensary. This was found by investors digging around. Nothing PR'd. I believe if this comes to fruition it will be the only dispensary that is publicly traded. The Clinics will be driving a lot of traffic to buy marijuana. NWAV
http://pao.group/store/
Rec, Have you taken a look at NWAV? Bottom Buster right now as well. Good time to take a position... I messaged Sleek months ago that for some reason I didn't think we would get a 4/20 this year...turns out I was right...at least it looks that way unless we get a surge next week. Anyway the gang that is in NWAV is not thinking 4/20 but this year or maybe even next year with the business plan NWAV has. Reverse Merger in late 2016 and they are in their first quarter of business. People invested are waiting for at least .25 or .50 or a Dollar is what I see getting thrown around on the message board. I saw an analysis the other day where the 3 Corporate Clinics alone are worth .27 not including the 3 affiliate Clinics. On this long weekend do some DD on it and read the stickies on the board too!!
NWAV
PAO Group, Inc. Anti-Opiate Crusade Charges on with Opening of Flagship Location in State of Ohio
http://ih.advfn.com/p.php?pid=nmona&article=74318199
PAO Group, Inc. Focusing on 2017 Growth Expansion Initiatives
http://ih.advfn.com/p.php?pid=nmona&article=72741925
NWAV ROADTRIP SUMMARY & REPORT
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130328503
St Augustine, Florida Medical Clinic
New: Investing in Marijuana MicroCap Stocks
Tuesday, March 10, 2015
By Alain Soutenet and Todd Davis
http://stocknewsnow.com/commentary/ANEWSID09032015100002/Investing-in-Marijuana-MicroCap-Stocks
V-LoveTM for Women is a desire gel and will be available for sale
http://finance.yahoo.com/news/enertopia-announces-v-love-tm-120100911.html
The second product launch will be the V-LoveTM infused with CBD from industrial hemp oil made and only available in the USA
EDXC CEO, Todd Davis, talking now on live webinar:
Invest in cannabis http://investincannabis.com/ecann-inc/ http://ecannabis.com Big things are coming to the cannabis sector get on the train or be left at the station
PMBS is a MMJ Winner $$$$$$$$$$$
an Amazing Ground Floor Opportunity Here !!
Strong Buy $$$$$$$$$$$$
http://www.puramedbioscience.com/
Huge news is being rumored for QEDN. A MUST on your watchlist.
Emerald Med Farm Tour Video:
$qedn is still undiscovered but when people realize they grow OG Kush it's lights out.
— Jason Spatafora (@WolfOfWeedST) June 4, 2014
DIDG$$ PR TODAY Mj programming...
"...MJ360's initial content includes the live streaming of the cannabis-lifestyle show, "Grass Roots," and "James Bong," a 420-inspired spy spoof. In addition, "Let's Be Blunt," a madcap reality show hosted by Kato Kaelin, described as "Girls Gone Wild" meets "Jerry Springer," will launch before the end of the month.
Other MJ360 strategic partnerships include online zines The Joint Blog and Smoking With Style, Skunk Magazine, a cannabis mag with 800,000 loyal readers, and online broadcaster Cult Radio A-Go-Go, whose weekly cult-movie radio show attracts over 500,000 listeners internationally.
"We're very excited about all of our new partnerships," added Greenwald, "and we're quite confident that the direct exposure to millions of cannabis users is acting as a lightning rod to attract viewership. It's a very exciting time for us at The Movie & Music Network as the internet broadcast space is expanding every month," he noted. "We continue adding subscribers as our programming attracts a wider audience..."
UNGS--- Finally done. This is the one folks.
Two MJ acquisitions.
Merger-- Signifi Solutions (have over 5 million in Rev's already)
Name changes.
Two new MJ websites live.
All this happening now... currently at .0014
NEWS NEWS NEWSAug 07, 2014 (ACCESSWIRE via COMTEX) -- ST. PETERSBURG, FL / ACCESSWIRE / Sylios Corp (otc pink:UNGS),
The development of products utilized in the medical and recreational marijuana industry is pleased to announce that the Company's Board of Directors elected to form a new wholly owned subsidiary for its cannabis operations.
On July 2, 2014, the Company filed with the State of Florida to form Bud Bank, LLC. The Company received approval from the Florida Office of Financial Regulation for the use of the name Bud Bank for its dispensing product. Bud Bank, LLC will be dedicated solely to the Company's cannabis dispensing product. The Company will continue to seek products to acquire, license or develop through joint ventures through its cannabis subsidiary, The Greater Cannabis Company, LLC.
The Company's two websites will be live the week of August 11, 2014. Sales of the Company's new cannabis dispensing product will be initiated upon launch of its website.
VMGI going through CAPITULATION get in now on the way back up!!!!
Cannabis can be used as an anti-cancer medicine -
QASP is closing or a couple deals. Also they are like the cheapest quality MJ plays out there... Run will follow shortly now.
UNGS IN a nut shell... MJ DISPENSING
We are excited to become part of US Natural Gas Corp," said Shamira Jaffer, President of Signifi. "This opportunity will allow us to leverage our collective knowledge and experience to build a stronger U.S. presence while augmenting our current retail channel strategies. Our new target markets will include emerging industries such as medical wellness and medical marijuana dispensing solutions where we see tremendous growth potential over the coming years.”
Followers
|
40
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
333
|
Created
|
01/15/14
|
Type
|
Free
|
Moderator TyTrades | |||
Assistants neophyte184 TStarr marklar3 OhManIDied |
Posts Today
|
0
|
Posts (Total)
|
333
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |